Despite its use since 1949, lithium remains a gold standard for bipolar disorder, though its exact biological mechanisms remain partially understood.
Key facts
- •Lithium was first introduced as a treatment for bipolar disorder in 1949.
- •The drug is administered as either lithium carbonate tablets or lithium citrate liquid.
- •Lithium helps regulate mood molecules such as dopamine and serotonin, which are often disrupted in bipolar patients.
- •The medication has a narrow therapeutic window, meaning the margin between an effective dose and a toxic dose is small.
- •Lithium's primary clinical benefit is its ability to prevent the relapse of manic or depressive episodes.
Lithium has served as a primary mood stabilizer for bipolar disorder since its clinical introduction in 1949. While modern psychiatry utilizes various medications to manage the condition's manic and depressive cycles, lithium is uniquely valued for its ability to address both poles of the disorder and prevent future relapses. The treatment currently affects approximately 36 million people worldwide who live with the condition.
By the numbers
Mechanism and Cellular Interaction
Lithium functions as a simple ion that can mimic sodium, allowing it to penetrate the interior of brain cells rather than acting solely on the cell surface. Once inside, it interacts with various cellular processes, including the inhibition of the enzyme glycogen synthase kinase 3. This enzyme influences gene activity, circadian rhythms, inflammation, and cell survival. Additionally, lithium supports autophagy—the process of clearing cellular debris and toxins—and enhances mitochondrial function. Despite these observed effects, researchers have not yet fully identified the precise underlying mechanism that produces its therapeutic benefits for bipolar disorder.
Clinical Challenges and Efficacy
The effectiveness of lithium varies significantly among patients. Clinical data suggests that approximately one-third of individuals experience profound benefits, one-third see intermediate results, and one-third do not respond to the treatment at all. Because the disorder is cyclic, determining long-term efficacy can take years. Lithium also presents a narrow therapeutic window, requiring careful management to avoid toxicity to the thyroid and kidneys. Common side effects reported by patients include increased urination and tremors. Because of these risks and the variable response rates, clinicians are currently researching ways to better identify which patients will benefit most from the treatment.
Advertisement
This article was independently rewritten by ManyPress editorial AI from reporting originally published by Live Science.
